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BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant
chemotherapy may improve survival, but targeting treatment to patients who respond to chemotherapy could be improved by the
availability of markers of response. This study sought proteomic markers of therapeutic response using an adenocarcinoma xenograft
model.
METHODS: Epirubicin, cisplatin or 5-fluorouracil was administered to severe combined immune-deficient mice bearing OE19
oesophageal adenocarcinoma xenografts. Murine plasma samples from treated and untreated xenografts were analysed by surface-
enhanced laser desorption/ionisation time-of-flight mass spectroscopy, and panels of peaks were found using class prediction models
that distinguished treatment groups. Proteins in these peaks were identified by mass spectroscopy in tryptic digests of purified
fractions. Five paired samples from oesophageal cancer patients before and after chemotherapy were analysed using the same
methodology.
RESULTS: Plasma protein peaks were identified that differed significantly (Po0.05, ANOVA) between the treated xenograft and
control groups. Marker panels predicted treated vs untreated xenografts with sensitivities of 100%, specificities of 86–100% and test
efficiencies of 89–100%. Three of the proteins identified in these panels, apolipoprotein A-I, serum amyloid A and transthyretin were
confirmed in the clinical samples.
CONCLUSION: Plasma protein markers can be detected in response to chemotherapy in oesophageal adenocarcinoma xenografts and
in clinical samples, and have the potential to monitor response and guide chemotherapy in oesophageal adenocarcinoma.
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The incidence of oesophageal cancer, particularly adenocarcinoma
in western populations, is increasing worldwide (Botterweck et al,
2000; Park, 2002; Lagergren, 2005) and carries a poor prognosis,
even in the minority with resectable disease (Gilbert et al, 2002;
Munro, 2004) for whom 5-year survival ranges from 10 to 35%
(Hulscher et al, 2002; Thompson et al, 2007). Trials of neoadjuvant
chemotherapy and neoadjuvant chemoradiotherapy have reported
mixed results ranging from no difference in curative resection or
overall survival (Kelsen et al, 2007) to improved resection rates
and survival (MRC Oesophageal Working Party, 2002; Geh et al,
2006). A systematic review of 11 randomised controlled trials
showed an increase in overall survival with the use of chemother-
apy, but statistical significance was only achieved after 5 years
(Maltaner and Fenlon, 2003). Palliative chemotherapy for
advanced oesophageal cancer results in control of symptoms in
70–80% of patients with 40–50% objective response rates but only
30–40% surviving for 1 year (Gilbert et al, 2002).
The ability to determine, at an early stage, which patients are
most likely to respond to chemotherapy could prevent patients
undergoing ineffective and potentially toxic treatments and allow
direction of treatment to those most likely to benefit. Imaging
techniques such as computerised tomography, magnetic resonance
imaging, endoscopic ultrasound and positron emission tomogra-
phy range in their effectiveness to predict response to chemother-
apy (Westerterp et al, 2005). Pathological criteria for assessment of
the degree of tumour regression in the resected oesophagus using
tumour regression grades may be a significant predictor of
disease-free survival (Mandard et al, 1994) but is not an
independent prognostic indicator for oesophageal adenocarcino-
mas (Dunne et al, 2001). Pathological response using modified
staging criteria has been shown to predict survival following
chemoradiotherapy (Swisher et al, 2005). In addition, pathological
response to pre-operative chemotherapy has been shown to
improve overall survival (Kelsen et al, 2007). However, neither
imaging techniques nor resectional pathology have to date
provided robust guidance of response during chemotherapy.
There has been growing interest in the use of proteomic
methods on peripheral blood plasma to rapidly profile protein
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smarkers that link expression of the genome with the disease
process (Cahill, 2001; Plebani, 2005) and to discover novel
biomarkers of therapeutic response (Smith et al, 2006). Liquid
chromatography methods such as high-performance liquid
chromatography and two-dimensional liquid chromatography
have been increasingly used for protein separation and mass
spectroscopy (MS) techniques, such as matrix-assisted laser
desorption ionisation time-of-flight, used to analyse the proteins
(Colantonio and Chan, 2005). The technique of surface-enhanced
laser desorption/ionisation time-of-flight (SELDI–TOF) MS, in
which chromatographic separation is achieved on a protein chip
surface and analysed intact (Colantonio and Chan, 2005), has been
investigated to identify serum and tissue proteomic profiles that
could be used in clinical diagnosis.
Surface-enhanced laser desorption/ionisation time-of-flight MS
has been reported to differentiate between responders and non-
responders treated with chemoradiotherapy (Hayashida et al,2 0 0 5 ;
Ota et al, 2007). In a single study of chemo-radiotherapy in patients
with squamous cell carcinoma of the oesophagus, a panel of four
peaks was identified, which distinguished chemo-radiotherapy
response in 14 out of 15 patients. Although the identity of these
markers was not reported (Hayashida et al, 2005), the performance
of this four-peak panel was superior to radiological and pathological
techniques in assessing response to therapy (Ota et al, 2007).
In this study, murine plasma protein profiles in mice bearing
human oesophageal adenocarcinoma xenografts, treated with three
clinically relevant chemotherapy agents: epirubicin, cisplatin or
5-fluorouracil, were used to detect in vivo candidate protein
markers of response to chemotherapy. The use of a genetically
homogenous host eliminates patient variables thus allowing a
focus on the effect of the drug on the adenocarcinoma xeno-
grafts. The approach taken was to identify markers that differed
significantly between normal and xenograft mice and/or differed
significantly between treated and untreated xenografts that have
potential use as clinical markers of response to chemotherapy.
An exploratory study of samples collected from patients with
oesophageal cancer before and after chemotherapy was used to test
the validity of this approach.
MATERIALS AND METHODS
Induction and treatment of xenografts and sample
collection
The OE19 oesophageal adenocarcinoma cell line was obtained
from the European Collection of Cell Cultures (www.ECACC.org)
and cultured in RPMI 1640 cell medium (Pall Laboratories,
Portsmouth, UK) under standard conditions. Cells were tested for
mycoplasma contamination using the mycoalert test (Cambrex Bio
Science, Nottingham, UK), collected for injection, placed in 50%
Matrigel (BD Biosciences, Bedford, MA, USA) and administered
(100ml) subcutaneously in the flank of severe combined immune-
deficient mice (Harlan, Loughborough, UK). The induction of
xenografts was monitored by twice weekly calliper measurements.
Groups of mice with established xenografts were injected with
clinically equivalent doses of epirubicin (epirubicin hydrochloride;
Calbiochem, Darmstadt, Germany) 30mg per 100ml (1.5mgkg
 1),
cisplatin (cis-diammine platinum II dichloride; Sigma-Aldrich,
Dorset, UK) 48mg per 100ml (2.4mgkg
 1) and 5-fluorouracil
(Fluka, Sigma-Aldrich) 240mg per 100ml (12mgkg
 1) or control
(water, 100ml) by intra-peritoneal injection once a week for up to
three injections (days 0.7 and 14). In addition, groups of control
mice not injected with tumour cells received the same doses of
drug or water control. At 24h after the last injection, mice were
killed and cardiac blood was collected into heparin plasma tubes
for analysis. Samples were separated and plasma was frozen at
 701C before analysis. All xenograft work was performed in
accordance with the UK Co-ordinating Committee on Cancer
Research guidelines under the requisite home office licences.
Collection of clinical samples
Samples were collected from five patients with oesophageal cancer
(four adenocarcinomas, one squamous cell carcinoma) before and
after chemotherapy. Of these five patients, three received
neoadjuvant chemotherapy (cisplatin, 5-fluorouracil; two cycles)
followed by surgery, one received neoadjuvant chemotherapy
(cisplatin, capecitabine; two cycles) followed by chemoradiation
therapy and one received palliative chemotherapy (mitomycin C,
cisplatin, capecitabine; three cycles). Pathological response follow-
ing surgery showed a partial response (tumour regression grade 3
or 4) in three of four patients. Samples were separated and plasma
was frozen at  701C before analysis. The patients were enrolled in
the study following written informed consent (Grampian Local
Research Ethics Committee).
Analysis of plasma samples by SELDI–TOF MS
Samples from each individual were denatured in 9 M urea and
tested at a final dilution of 1:100 on CM10 (weak cation
exchanger) protein chips pre-equilibrated with 50mM citrate (pH
4) and Q10 (strong anion exchanger) protein chips pre-equili-
brated with 50mM phosphate (pH 6). The chips were washed and
sinapinic acid was added as matrix according to the manufac-
turer’s recommended methods (Bio-Rad, Hemel Hempstead, UK),
analysed using a SELDI–TOF MS PSII instrument (Bio-Rad) with
an all-in-one protein standard (Ciphergen, Fremont, CA, USA)
included on each run. Spectra for each individual were collected
over a low molecular weight range (2000–30000) and high
molecular weight range (20000–150000) using fixed (optimised)
laser intensity and detector sensitivity settings. Data collected from
multiple points on each spot were collated into averaged spectra
using the instrument software. The spectra from each experiment
were normalised using the total ion current and calibrated from
the all-in-one protein standard data. Peaks were detected using the
instrument’s biomarker software, using a peak threshold of 20%, a
first pass signal/noise ratio of 5 and a second pass signal/noise
ratio of 3. The reproducibility of this method, assessed by repeat
testing of a sample yielded typical CVs of 20% in the low molecular
weight analyses and 30% in the high molecular weight analysis,
was consistent with reported data (Semmes et al, 2005). Sample
statistics were generated for peaks identified using the biomarker
software. For each sample group test performed, a list of peak
intensities analysed and P-values (ANOVA) obtained was
recorded. The above procedure was followed for the analysis of
both human and murine samples. An additional analysis was
performed on samples from xenografts to correct for the effect of
tumour burden. Spectra were selected from untreated and treated
xenografts that were matched for tumour volume. Sample statistics
were generated to test for significant differences in peak intensities
between treated and untreated xenografts (for each drug) in these
matched groups. All peaks with Po0.05 (95% confidence limit)
were considered to be significant. The murine xenograft data were
further analysed using pattern recognition software (Genespring
GX; Agilent Technologies, Santa Clara, CA, USA). Following
published methods (Villanueva et al, 2007), we performed an
unsupervised hierarchical clustering according to peak m/z and
condition using principal component analysis to detect clustering
in relation to each treatment group. To control for non-specific
effects of drug treatment that were unrelated to tumour response,
we excluded data for peaks that differed significantly between
treated and untreated non-xenografts from the analysis and class
prediction was performed using K-nearest neighbours and Support
Vector Machine using peak m/z lists created by one-way ANOVA,
ranked by P-value and delimited using P-value cut-offs. This
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sensures that only the most highly significant markers are included
in each panel and the cut-off can be varied to obtain the optimal
class prediction model with the smallest number of panel
members. For each test parameter the class prediction model
was optimised using a training set comprising B75% of the
samples, and validated using an independent test set comprising
B25% of samples, both sets comprising all treatment groups.
Protein identification
Peaks from one or more panels that predicted treated vs untreated
xenografts were selected for protein identification by fractionation
followed by MS/MS. Murine samples containing high intensity
peaks to be identified were denatured in 9 M urea and fractionated
using Q Ceramic Hyper D spin columns equilibrated in 1 M urea
(pH 9) and eluted in buffers ranging from pH 9 to pH 3, followed
by an organic solvent (columns and buffers all sourced from Bio-
Rad). Eluted fractions were spotted on to protein chip surfaces
(NP20, H50, Q10 (pH 4) and CM10 (pH 6)) and further analysed by
SELDI–TOF MS to determine the fractions containing the target
peak (m/z). Further murine and human samples were fractionated
using an off-gel fractionator fitted with 24cm IPG strips according
to the manufacturer’s instructions (Agilent Technologies). Selected
fractions were concentrated and desalted in 10mM HEPES using
molecular weight cut-off filters (Vivaspin; Sartorius, Goettingen,
Germany). The retentates were tested by SELDI MS using CM10,
Q10, H50 and/or NP20 protein chips to confirm the optimal
location of the peak of interest. The desalted fractions were
reduced in 10mM DTT (10min incubation at 701C), alkylated in
50mM iodoacetamide (30min incubation at room temperature)
and loaded onto nu-PAGE 10–20% Tricine, 10 or 12% Bis-Tris gels
(Invitrogen, Carlsbad, CA, USA) with MES running buffer and run
with SeeBlue Plus 2 pre-stained standards (Invitrogen). Electro-
phoresis was performed at 125V for 70–90min (Tricine gels) or
200V for 35–40min (Bis-Tris gels). Gels were fixed with 50%
methanol/10% acetic acid and staining was performed with
Coomassie G-250 colloidal stain (Invitrogen) for 3–12h and
destained with deionised water overnight. Selected protein bands
were excised from gels using a Harris Unicore 1mm cutter (Sigma-
Aldrich). Proteins were passively eluted from the gel pieces to
confirm the presence of the peaks of interest by SELDI MS using
CM10, Q10, H50 and/or NP20 protein chips. Matched gel pieces
were processed and in-gel digested with Trypsin (Roche, Welwyn,
UK) and an aliquot of the digest analysed by nLC-MS-MS using a
4000 QTRAP (Applied Biosystems, Carlsbad, CA, USA). The
tandem MS data generated from the observed peptides were
analysed and identified using the Mascot search engine (www.ma-
trixscience.com) against the NCBInr and IPI Mouse databases.
Only peptides that had ion scores above the significance threshold
were reported and grouped into their respective protein identifica-
tions, with MOWSE scores indicating probability of correct
identification. Peptide sequences obtained were mapped on the
known protein sequence to determine the percentage of the
sequence covered. Proteins identified with less than two peptides
and ion scores below the significance threshold were subsequently
confirmed and validated by targeted nLC-MS-MS on an LTQ
Orbitrap XL Ion Trap (Thermo Fisher Scientific, Loughborough,
UK). In this mode tryptic peptides of known m/z values are
generated from the theoretical protein sequence and then used as a
target list during nLC-MS-MS analysis. Duplicate fractionation and
analyses were undertaken to confirm and validate the identifica-
tion of peaks with initial low probability ion scores.
RESULTS
Oesophageal adenocarcinoma OE19 xenografts treated with
cisplatin, epirubicin or 5-fluorouracil showed significant growth
reduction with all three drugs when compared with matched
untreated controls (Figure 1), at the time points indicated
(Po0.05, two-tailed t-test, assuming equal variance or
Mann–Whitney test as appropriate).
Profiles of the murine plasma sample proteins obtained using
SELDI–TOF MS on the two (CM10 and Q10) chip surfaces allowed
detection of 189 peaks that were present in most samples. A
preliminary assessment of this data indicated that statistically
significant (Po0.05) differences were observed for multiple peak
intensities between xenografts and controls, treated and untreated
xenografts as well as treated and untreated non-xenografts for all
three drug treatments. Significant differences were detected











































































































01 4 10 7 3
01 4 11 7 4
01 1 7 4
Figure 1 Tumour volume data obtained during treatment of OE19
xenograft bearing mice with each drug (epirubicin, n¼20, cisplatin, n¼16
and 5-fluorouracil, n¼18 or control (blank, n¼23, 20 and 12 respectively).
Mean tumour volumes normalised to day zero (first day of drug injection)
and 95% confidence intervals are shown and statistically significant
differences (Po0.05, two-tailed t-test or Mann–Whitney test as
appropriate) are highlighted (*).
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sbetween treated and untreated xenografts that were matched for
tumour volume at the time of sample collection, indicating that these
differences in response to therapy were not simply caused by changes
in tumour burden. Pattern recognition software was therefore used to
further elucidate these findings. An initial assessment by principal
component analysis performed on this data set (with principal
components X, Y and Z) and plotted as a three-dimensional map
showed unsupervised clustering of samples according to treatment
group (Figure 2). The data were therefore further analysed to
determine whether panels of markers could be used to predict the
class (treatment group) of each sample. To control for non-specific
effects of drug treatment that were unrelated to tumour response, we
excluded data for peaks that differed significantly between treated and
untreated non-xenografts from this analysis. The most highly
significant markers were selected in these panels, by ranking
according to P-value and application of a P-value cut-off. The class
prediction results are summarised in Table 1 with the number of
(statistically significant, Po0.05, following P-value cut-off selection)
peaks selected for the class prediction model indicated for each test
performed. Following optimisation of the k nearest neighbours and
the Support Vector Machine algorithms using the training set, we
tabulated the output obtained for the independent test set using the
optimal model in terms of the number of samples correctly predicted
and the number of samples incorrectly predicted. From these
predictions, calculated sensitivity, specificity, positive and negative
predictive value (PPV and NPV) and overall test efficiency for
xenograft-bearing mice vs mice without xenografts (Table 1a) and
treated vs untreated xenografts for each drug (Table 1b) show the test
method accuracy using the selected panels of protein peaks.
Fractionation of the murine plasma to isolate the protein peaks
selected from the class prediction modelling and protein
fingerprint analysis of the tryptic digests of these isolated protein
peaks resulted in the identification of seven proteins (Table 2),
with high MOWSE probability scores and sequence coverage
ranging from 24 to 84%. The sequence data indicated that each
of these proteins was murine in origin. The proteins identified
include markers selected in the class prediction models as
annotated (Table 2). Hence this table includes markers that
predict presence of tumour and/or response to chemotherapy.
Analysis of the human sample SELDI–TOF MS spectra resulted
in the detection of a number of peaks that differed significantly
(Po0.05) between the pre-chemotherapy and post-chemotherapy
samples. Fractionation of the human samples and protein
fingerprint analysis of these peaks resulted in the identification
of four proteins (Table 3) with high MOWSE probability scores
and sequence coverage ranging from 42 to 87%. Three of the eight
proteins (serum amyloid A (SAA), transthyretin and apolipopro-
tein A-1) identified in the murine plasma were confirmed in the
human samples, with the identification of one additional protein
(retinol-binding protein 4) in the human samples only. Of these
four markers, three were increased after chemotherapy and one,
SAA, decreased.
DISCUSSION
The ultimate intent of this research programme is to develop
biomarkers predictive of response to therapy in oesophageal
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Figure 2 Principal component analysis of plasma profiles obtained in the
mouse xenograft experiments. Each point represents a single sample,
colour coded as indicated according to untreated xenograft (epirubicin,
cisplatin or 5-fluorouracil) treated xenograft, untreated non-xenograft or
treated non-xenograft mouse.
Table 1 Summary of class prediction data
(a) OE19 xenograft-bearing mice vs non-xenograft control mice
Number of
peaks (m/z)















22 19 1 92.3 100 100 87.5 95.0
(b) Treated vs untreated OE19 xenograft-bearing mice

















Epirubicin 9 11 0 100 100 100 100 100
Cisplatin 7 10 1 100 85.7 80.0 100 90.9
5-FU 14 8 1 100 85.7 66.7 100 88.9
Abbreviations: 5-FU¼5-fluorouracil; PPV¼positive predictive value; NPV¼negative predictive value.
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scandidate circulating biomarkers in mice bearing oesophageal
adenocarcinoma xenografts. Proteins were identified that could
distinguish groups of xenograft vs non-tumour-bearing mice and/
or treated and untreated xenograft-bearing mice. As such, the
candidate markers have potential as diagnostic markers of
oesophageal cancer and/or markers of response to therapy. A
pilot study using clinical samples confirmed that three of these
candidate markers changed significantly after chemotherapy.
The xenograft model of adenocarcinoma used clinically
equivalent doses of epirubicin, cisplatin and 5-fluorouracil, which
were effective at reducing growth in the OE19 xenografts (Figure 1).
Analysis of the plasma samples taken from the mice by SELDI–
TOF MS enabled the identification of multiple peaks that differed
significantly between xenograft-bearing and control mice, or
between treated and untreated xenograft-bearing mice. Differences
between treated and untreated xenografts were evident after these
groups were matched for tumour burden at the time of sample
collection, indicating that the observed differences reflected
response to chemotherapy. Further analysis of the plasma profiles
gave evidence of clustering within treatment groups, and class
prediction models clearly showed that a panel of peaks was able to
discriminate between xenograft-bearing mice and controls, with
sensitivity of 92% and specificity of 100%. In addition, unique
panels of peaks were able to discriminate between treated and
untreated xenografts for each drug (Table 1), with sensitivities of
100% and specificities of 86–100%. Hence, the observed response
of human oesophageal adenocarcinoma xenografts to chemo-
therapy was associated with detectable changes in plasma protein
profiles and further work focused on identifying the protein peaks
represented in the treatment class prediction models.
The protein peaks identified in the mouse xenograft samples
were well-characterised circulating murine proteins. This suggests
we have identified host rather than tumour proteins that indicate
the presence of tumour and/or response to chemotherapy. None of
the proteins reported in this study has previously been related to
therapeutic response in oesophageal cancer. These proteins are
high rather than low-abundance proteins, as has commonly been
the case in proteomic studies of serum or plasma in which the top
20 most abundant proteins represent some 98% of total protein.
In this study the decision was taken not to immunodeplete the
samples of high-abundance proteins, to ensure that all candidate
markers were considered, given the observation that these
immunodepletion methods can also deplete samples of low
abundance markers that are associated with the abundant carrier
proteins (Granger et al, 2005).
Apolipoprotein A-1 was in the xenograft vs non-tumour-bearing
mouse class prediction panel as well as the panels for epirubicin or
5-fluorouracil-treated vs -untreated xenografts, suggesting an
abnormality in the presence of xenograft that is corrected by
treatment. Although this proteomic response is novel in the context
of oesophageal cancer, apolipoprotein A-I has previously been
reported as a serum marker for the detection of cancer, with a
reduction in breast (Huang et al, 2006), pancreatic (Ehmann et al,
2007) and colorectal (Engwegen et al, 2006) cancers when compared
with healthy controls. Apolipoprotein C-III was in the panel for
5-fluorouracil-treated vs -untreated xenografts. Changes in other
apolipoproteins, including apolipoprotein C-III, have also been
reported (Huang et al, 2006). Like apolipoprotein A-1, transthyretin
was in the panel for the xenograft vs non-tumour-bearing mice as
well as for epirubicin or cisplatin treated vs untreated xenografts.
Transthyretin (also known as thyroxin-binding prealbumin) has
also been reported as a marker, decreased for ovarian (Zhang et al,
2004) and increased for lung (Maciel et al, 2005) cancer.
b-2-Microglobulin was in the panel for epirubicin-treated vs
untreated xenografts. This marker has been proposed as a
prognostic marker for myeloma (Jacobson et al,2 0 0 3 ) .
Serum amyloid A was in the panel for xenografts vs non-
tumour-bearing mice but not in the panels for treated vs untreated
xenografts. Increased SAA, an acute-phase protein produced by
hepatocytes of the liver (Raynes et al, 1991), has also been
identified as a significant marker in various cancers including lung
(Dowling et al, 2007), nasopharyngeal (Liao et al, 2008) and gastric
(Wang et al, 2008) carcinomas by many techniques including MS
and immunoassay. Two other markers included in the panel for
xenograft vs non-xenograft mice were identified as haemoglobin
chains. Changes of haemoglobin have been reported previously for
breast cancer (Huang et al, 2006). Tumour anaemia is a common
symptom in cancer patients and haemoglobin levels are associated
Table 2 Identification of significant proteins
m/z Predictive for
a Protein (mouse) MOWSE score No. of peptides Sequence covered (%)
8880 4 Apolipoprotein C-III 1048 24 64
11680 2 b-2-microglobulin 384 22 57
11750 1 Serum amyloid A 358 14 63
14040 1, 2, 3 Transthyretin 271 5 24
15830 1 Haemoglobin b-2 648 14 82
16020 1 Haemoglobin b-1 1145 20 84
28880 1, 2, 4 Apolipoprotein A-I 731 20 50
a1¼xenograft vs non-xenograft; 2¼epirubicin-treated vs -untreated xenograft; 3¼cisplatin-treated vs untreated xenograft; 4¼5-fluorouracil-treated vs -untreated xenograft.
For each peak (m/z), the treatment for which the peak was predictive, the protein identified, the MOWSE probability score and sequence coverage is shown.
Table 3 Identification of significant proteins in clinical samples
m/z Protein (mouse) Approx. MW MOWSE score No. of peptides Sequence covered (%)
11600 Serum amyloid A 11700 1131 37 69
14000 Transthyretin 14000 2181 66 83
21000 Retinol-binding protein 4 21100 1050 46 77
28200 Apolipoprotein A-I 28000 1854 58 42
Abbreviation: MW¼molecular weight. For each peak (m/z), the protein identified is shown, together with the expected MW in plasma, the MOWSE probability score and
sequence coverage.
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swith survival for ovarian (Obermair et al, 1998) and lung (Tomita
et al, 2008) cancers.
Thus, the proteins identified by the present studies have been
suggested as cancer markers for many tumour types, but have not
previously been reported as markers for oesophageal cancer. The
initial finding that three of the markers identified in the mouse
xenograft model were also identified in patient samples confirms
the benefit of the experimental approaches used. Although at
present SAA, transthyretin and apolipoprotein A-1 as individual
markers may be too non-specific to influence therapeutic
decisions, taken together, these plasma proteins may represent a
panel of circulating markers that provide information about
response to therapy in oesophageal cancer. To date we have only
looked at a relatively small number of patients with some evidence
of pathological response but have not been able to compare the
biomarker pattern observed with other indicators of clinical
response. Prospective testing of these plasma proteins as markers
of response to chemotherapy within clinical trials, comparing
responders to non-responders, is now required.
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